---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001023"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:50:49.129235+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics amends bylaws for universal proxy rules and DGCL updates

## Summary
- Amended bylaws effective Jan 19, 2023, addressing SEC universal proxy rules (Rule 14a-19) and recent DGCL amendments.
- Revised advance notice provisions require additional disclosures, limit nominees to board seats available, and mandate nominee interviews.
- New rule requiring universal proxy solicitors to use non-white proxy cards; stockholders must certify compliance with Rule 14a-19.
- Added emergency bylaw provision for board/quorum during crises; updated electronic notice procedures.
- Updates to stockholder meeting conduct, including attendance procedures and Rule 14a-8 proponent rules.

## SEC filing metadata
- accession: 0000950170-23-001023
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/0000950170-23-001023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/prld-20230119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001023
- JSON: https://secwatch.observer/filing/0000950170-23-001023.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001023.txt

## Key facts
- Governance Changes
  Prelude Therapeutics Inc: Adopted amended and restated bylaws to implement changes related to universal proxy rules, recent DGCL amendments, and other procedural and administrative updates, effective January 19, 2023 (effective 2023-01-19).
  - Change: bylaw amendment
  - Effective: 2023-01-19
  source text: On January 19, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Prelude Therapeutics Incorporated (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023001023/0000950170-23-001023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.